このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Ascentage Pharma Group International 将来の成長

Future 基準チェック /36

Ascentage Pharma Group International利益と収益がそれぞれ年間13.2%と20%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に770.7% 19.5%なると予測されています。

主要情報

13.2%

収益成長率

19.5%

EPS成長率

Biotechs 収益成長	35.4%
収益成長率	20.0%
将来の株主資本利益率	770.7%
アナリストカバレッジ	Low
最終更新日	28 Aug 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:36X - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,285	63	-668	N/A	4
12/31/2025	483	-924	-899	N/A	4
12/31/2024	1,020	-307	-647	N/A	4
6/30/2024	903	-360	N/A	N/A	N/A
3/31/2024	563	-643	N/A	N/A	N/A
12/31/2023	222	-926	-783	-726	N/A
9/30/2023	239	-902	-798	-707	N/A
6/30/2023	257	-879	-814	-687	N/A
3/31/2023	233	-881	-852	-671	N/A
12/31/2022	210	-883	-891	-654	N/A
9/30/2022	160	-848	-922	-620	N/A
6/30/2022	111	-812	-954	-586	N/A
3/31/2022	69	-797	-997	-595	N/A
12/31/2021	28	-782	-1,041	-605	N/A
9/30/2021	25	-759	-1,021	-635	N/A
6/30/2021	23	-735	-1,000	-665	N/A
3/31/2021	18	-706	-931	-637	N/A
12/31/2020	12	-678	-861	-610	N/A
9/30/2020	14	-922	-798	-576	N/A
6/30/2020	15	-1,167	-735	-542	N/A
3/31/2020	15	-1,324	-638	-501	N/A
12/31/2019	15	-1,481	-542	-460	N/A
9/30/2019	11	-1,171	-454	-399	N/A
6/30/2019	7	-862	-366	-338	N/A
3/31/2019	7	-604	-310	-288	N/A
12/31/2018	7	-345	-253	-238	N/A
12/31/2017	6	-119	N/A	-108	N/A
12/31/2016	8	-108	N/A	-46	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 36X今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 36X今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 36X今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 36Xの収益 ( 33.1% ) German市場 ( 5.1% ) よりも速いペースで成長すると予測されています。

高い収益成長: 36Xの収益 ( 20% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 36Xの自己資本利益率は、3年後には非常に高くなると予測されています ( 770.7 %)。

Ascentage Pharma Group International 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2026

Forecast to breakeven in 2023

Recent updates

Forecast to breakeven in 2026

First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023)

New major risk - Revenue and earnings growth

Ascentage Pharma Clears to Initiate A Registrational Phase III Study of Lisaftoclax, by the Center for Drug Evaluation of China National Medical Products Administration

Ascentage Pharma Group International to Report First Half, 2024 Results on Aug 22, 2024

New minor risk - Shareholder dilution

Ascentage Pharma Announces Updated Results from Three Studies of Olverembatinib (HQP1351)

Ascentage Pharma Group International Announces Board and Committee Changes

New major risk - Share price stability

Ascentage Pharma Releases Updated Clinical Data of olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%

Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates in 2024 American Society of Clinical Oncology Annual Meeting

Ascentage Pharma Group International, Annual General Meeting, May 10, 2024

Full year 2023 earnings released: CN¥3.28 loss per share (vs CN¥3.35 loss in FY 2022)

Ascentage Pharma Group International to Report Fiscal Year 2023 Results on Mar 27, 2024

Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib (HQP1351) in Patients with Chronic-Phase Chronic Myeloid Leukemia

Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN)

Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib

Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR

Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication

China National Medical Products Administration Approves Olverembatinib for Treatment of Cml-Cp Patients

Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology(ASH) Annual Meeting, two of which have been Selected for Oral Reports

Ascentage Pharma Releases Latest Data of Pelcitoclax (Apg-1252) Combined with Osimertinib Demonstrates Potential as A New Treatment Option for Tp53-And Egfr-Mutant Nsclc

Ascentage Pharma Announces First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia

Ascentage Pharma Announces Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment Naïve Patients with CLL/SLL Approved by the China CDE

First half 2023 earnings released: CN¥1.47 loss per share (vs CN¥1.54 loss in 1H 2022)

Ascentage Pharma Announces Clearance for Global Registrational Phase III Trial

Ascentage Pharma Group International to Report First Half, 2023 Results on Aug 21, 2023

Ascentage Pharma Group International Receives Clearance from the U.S. Food and Drug Administration to Initiate A Phase 3 Registrational Trial of Lisaftoclax

New minor risk - Share price stability

Ascentage Pharma Group International Announces CDE's Approval for the Phase III Pivotal Study in China of Olverembatinib for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ All)

Ascentage Pharma Group International Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC

Ascentage Pharma Group International Recommends Breakthrough Therapy Designation in China for the Treatment of Sdh-Deficient GIST

Ascentage Pharma Group International Presents Results from Four Studies at 2023 American Society of Clinical Oncology Annual Meeting

Full year 2022 earnings released: CN¥3.35 loss per share (vs CN¥3.07 loss in FY 2021)

Ascentage Pharma Group International has completed a Follow-on Equity Offering in the amount of HKD 550.125 million.

Ascentage Pharma Group International's Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List

Ascentage Pharma Group International Releases Preliminary Results from a Global Phase II Study of Lisaftoclax

Ascentage Pharma Delivers Oral Report on the First Dataset from the US Study of Olverembatinib (HQP1351) with Promising Efficacy Observed in Patients Who Failed Prior Treatment with Ponatinib

Ascentage Pharma's Global Industrial Base Obtains Drug Production Enterprise License

Ascentage Pharma Group International Announces IND Approval in China for Phase I Study of APG-5918 in Patients with Advanced Solid Tumors or Hematologic Malignancies

Ascentage Pharma Group International Announces Released Results from A Phase I Study of the Investigational Inhibitor of Apoptosis Protein (Iap) Antagonist Apg-1387 in Chinese Patients with Chronic Hepatitis B

Ascentage Pharma Releases Phase I Results of Iap Antagonist Apg-1387 in an Oral Report Showing Potential for Functionally Curing Chb

Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, At the ASH Annual Meeting

Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting

Ascentage Pharma Announces Phase I/Ii Data of Olverembatinib (Hqp1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-In-Class Potential

First half 2022 earnings released: CN¥1.54 loss per share (vs CN¥1.53 loss in 1H 2021)

Ascentage Pharma Group International to Report Q2, 2022 Results on Aug 26, 2022

High number of new directors

Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada

Ascentage Pharma Announces China National Medical Products Administration Accepts and Grants Priority Review Designation to Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML

Ascentage Pharma Group International Announces Ind Clearance by the Us Fda for First-In-Human Study of Novel Eed Inhibitor Apg-5918

Ascentage Pharma Group International Releases Results from A Phase I Study of the Company's Novel Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R Nhl) at the 2022 European Hematology Association Hybrid Congress

Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL

Ascentage Pharma Releases for the First Time Results of its FAK/ALK/ROS1 inhibitor APG-2449 Demonstrating Safety and Efficacy in Patients with Advanced NSCLC

Ascentage Pharma Group International Releases the Updated Results from A Phase II Study of the Mdm2-P53 Inhibitor Alrizomadlin (APG-115) Plus Pembrolizumab in Adults and Children with Various Solid Tumors in A Poster Discussion Session At the ASCO Annual Meeting

Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development

High number of new directors

Ascentage Pharma Group to Present Latest Clinical Data of Bcl-2 Inhibitorlisaftoclax (Apg-2575) in Patients with Relapsed/Refractory Non-Hodgkinlymphomas At 2022 European Hematology Association Hybrid Congress

Ascentage Pharma Group International Announces Management Changes, Effective May 20, 2022

Ascentage Pharma Group International Announces Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19 Published in Embo Molecular Medicine

Less than half of directors are independent

Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022

Ascentage Pharma Group International, Annual General Meeting, May 19, 2022

Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including A China Study Demonstrating Complete Responses

Ascentage Pharma Announces CDE's Approval for the Phase II Pivotal Study in China of the Bcl-2 Inhibitor Lisaftoclax (APG-2575) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Clover Biopharmaceuticals, Ltd. and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human Trail-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal Carcinomatosis

Ascentage Pharma and Innovent Biologics Announce Approval for China's First Third-Generation BCR-ABL TKI Olverembatinib

Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Grants Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma

Ascentage Pharma Reports the Phase Ib Results of the Dual Bcl-2/Bcl-Xl Inhibitor, Apg-1252

First half 2021 earnings released: CN¥1.53 loss per share (vs CN¥1.53 loss in 1H 2020)

Ascentage Pharma Group International Receives Orphan Drug Designation by the FDA for the Treatment of Stage IIB-IV Melanoma

Ascentage Pharma Announces IND Clearance by the US FDA for Lisaftoclax (APG-2575) as Single Agent or in Combinations for the Treatment of ER+ Breast Cancer and Other Solid Tumors